FORTIFI-HN01
59 evidence topics · 15 sources
Objective
Study purpose in the ClinicalTrials.gov record
Phase 2 and phase 3 objectives in the EU trial record
Study question in the updated trial-in-progress poster
Location and study date
Study dates and sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2025-01-28” |
| Primary completion (estimated) | “2028-04” |
| Study completion (estimated) | “2029-07” |
| Sites | “This study has 231 locations” |
Enrollment regions in the updated trial-in-progress poster
First enrollment in the annual report
Study design
Seamless phase 2 and phase 3 design in the ClinicalTrials.gov record
Blinding in the EU trial record
Stratification factors in the updated trial-in-progress abstract
Phase 2 dose decision rule in the initial trial-in-progress poster
Dose optimization run-in in the annual report
FDA dose-optimization guidance on randomized dose comparison
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record
Primary site and histology in the EU trial record
HPV assay developer named in the EU trial record
| Third party | Quoted record |
|---|---|
| Organization | “Qiagen Manchester Limited” |
| Duty delegated by the sponsor | “Development of HPV DNA Assay” |
Prior-therapy criteria in the EU trial record
Measurable disease, performance status, and age in the EU trial record
Bleeding risk exclusion in the EU trial record
Central laboratory HPV confirmation in the initial trial-in-progress abstract
Central laboratory HPV confirmation in the updated trial-in-progress abstract
Key eligibility criteria in the updated trial-in-progress poster
Population description in the first-enrollment press release
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Quoted regimen |
|---|---|
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C and Phase 3 Arm C (placebo comparator) | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 OBD Arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
Route, schedule, and duration in the updated trial-in-progress abstract
Selected phase 3 dose and phase 2 crossover in the updated trial-in-progress poster
Study outcomes
Rationale for using RECIST v1.1 objective response rate and overall survival as the primary endpoints
Primary endpoints in the ClinicalTrials.gov record
Primary endpoints in the EU trial record
Secondary endpoints in the ClinicalTrials.gov record
Patient-reported outcome endpoints in the ClinicalTrials.gov record
Endpoint roles and tumor assessment schedule in the updated trial-in-progress abstract
Endpoint roles in the updated trial-in-progress poster
Regulatory basis for the response and survival endpoints in the annual report
Regulatory basis in the first-enrollment press release
FDA endpoint guidance on objective response rate and overall survival
FDA draft guidance on one randomized trial for accelerated approval and verification of benefit
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment in the updated trial-in-progress abstract
Planned enrollment in the updated trial-in-progress poster
Description of analysis sets
Response analysis sets in the ClinicalTrials.gov record
Phase 2 participants contributing to the primary analyses in the annual report
Interim and final analyses in the trial-in-progress materials
Interim analysis timing in the third-quarter results press release
Results
Participant disposition
First enrollment in the press release
Completion of phase 2 and transition to phase 3 in the annual report
Phase 2 arm disposition in the updated trial-in-progress poster
Baseline characteristics
No evidence found.
Efficacy results
Phase 2 dose selection outcome in the press release
Data informing dose selection in the annual report
Biomarker basis for dose selection in the full-year results press release
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
FORTIFI-HN01 has reported no efficacy, safety, or baseline results; the phase 3 dose selection rests on company statements that it was informed by the open-label phase 1/1b data sets and by data from the phase 2 treatment arms. Accelerated approval would rest on an interim ORR analysis, with clinical benefit verified by OS in the same trial, the design FDA draft guidance calls the “one-trial” approach; FDA draft guidance states that preserving trial integrity is critical to that approach, and Bicara states that “interim and preliminary data may not be predictive of final results” and that confirmatory studies may not show clinical benefit. The control arm is placebo plus pembrolizumab 200 mg every 3 weeks, and participants treated at 1500 mg weekly in phase 2 contribute to the primary analyses while those treated at 750 mg weekly do not.